LONDON - The European diabetes diagnostics market is poised for expansion with segments such as self-monitoring and point-of-care (POC) tests offering tremendous growth potential. Heightened efforts to generate awareness about diabetes and related diagnostic tests are a key driver in market development. For instance, limited awareness about HbA1C tests is restraining the laboratory market. However, this challenge will be curtailed with more education about the test.
(Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)
New analysis from Frost & Sullivan (www.drugdiscovery.frost.com) European Diabetes Diagnostics Market, finds that the market earned revenues of $3.6 billion in 2008 and estimates this to reach $10.6 billion in 2015. The following segments are covered in this research: laboratory HbA1C testing, self-monitoring blood glucose (SMBG) and POC diabetes testing.
“The increasing prevalence of diabetes along with the demand for more rapid tests drives the market, especially for the SMBG segment,” notes Frost & Sullivan Programme Leader Arun A.K. “Efforts are being undertaken to popularise HbA1C tests and enhance the adoption rate in POC settings.”
Type-2 diabetes is asymptomatic in nature; therefore, emphasis is placed on early diagnosis of the disease. Along with early diagnosis, patients are recommended to use self-test meters at home. The rising interest in self-testing has opened opportunities for emerging technologies such as minimally invasive and non-invasive blood glucose meters.
Low awareness and poor communication between manufacturers and physicians is a challenge for the HbA1C market. Different laboratories have varied methods of measuring HbA1C, leading to inconsistency in results.
“Manufacturers must diversify into other segments in order to maintain growth momentum in the diabetes diagnostics market,” explains Arun. “Improved coordination between physicians and the patient community is the best way to produce customised solutions in the market.”
In addition to high-quality products, market participants must provide additional support to end users. Round-the-clock customer service and exceptional technical support are essential to succeed in this fiercely competitive market.
“Manufacturers must create awareness about the importance of diabetes diagnostics tests,” says Arun. “Resources need to be allocated exclusively for marketing and distribution services.”
If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, a brief brochure will be sent to you by e-mail.
European Diabetes Diagnostics Market is part of the Drug Discovery & Clinical Diagnostics Growth Partnership Service programme, which also includes research in the following markets: European POC Connectivity Market, Strategic Analysis of the European Autoimmune Diagnostics Market, European Cancer IVD Market and Western European IVD Market. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 35 offices on six continents. To join our Growth Partnership, please visit www.frost.com.
European Diabetes Diagnostics Market M2ED Contact: Katja Feick Corporate Communications - Europe P: +49-(0)-69-7703343 E: katja.feick@frost.com www.frost.com
Source: Frost & Sullivan
Katja Feick of Frost & Sullivan Corporate Communications - Europe, +49-(0)-69-7703343, katja.feick at frost.com ; Photo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO
Related Press Releases
Survey Reveals Diabetics Feel the Condition Impacts on Their Mood and Sex LifeAugust 26th, 2009 LONDON - A new research study carried out by The Research Partnership reveals that living with diabetes can have a major effect on people's lives, with just under half (44%) of type 2 patients reporting that the condition has impacted on either their ability or their desire to have sex. The study was conducted online amongst 2,000 patients with type 2 diabetes living in the US, UK and Germany and investigated patients' attitudes, feelings, health status, drug treatment programmes and needs for coping with life with diabetes.
Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion, Reveals Frost & SullivanAugust 18th, 2009 LONDON -
Increasing knowledge related to the pathology of diabetes will support the introduction of improved drugs to treat the disease. As healthcare moves towards the ideal of preventive medicine, there are a few companies conducting research on diabetes vaccines.
Long-term Investment Secured - Swiss Foundation Supports Innovative Concept for Patients With DiabetesJuly 2nd, 2009 ZÜRICH - Solianis recently signed an investment agreement with a Swiss foundation which invests its assets in Swiss companies. According to the agreement, this foundation will put CHF 5 million, while the previous investors in Solianis are investing another CHF 3 million.
Hospital Information Systems (HIS) Markets in Europe: Frost & Sullivan Reveals the Cost, Crunch and the Care ValueJune 28th, 2009 LONDON -
The Healthcare Group at Frost & Sullivan is pleased to announce its 2009 Quarterly Analyst Briefing Presentation on the European Hospital Information Systems (HIS) Market to be held on Tuesday, 7th July 2009, at 2 p.m. GMT. (Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)
Although most hospitals in Europe have some kind of information system in place, only a few have fully integrated and functional hospital information systems solutions installed.
Reminder: Sanofi Aventis - Live Webcast: Breaking News From the American Diabetes Association 69th Scientific SessionsJune 4th, 2009 NEW ORLEANS - What Live Webcast: Delivering real patient benefit: Update on new clinical excellence & future company vision Live from the American Diabetes Association 69th Scientific Session When Sunday, June 7th, 2009 10:30am - 11:30am CDT (Central Daylight Time) New Orleans, Louisiana, USA 17:30pm - 18:30pm CEST (Central European Summer Time) Paris, France
How to register www.videonewswire.com/event.asp?id=59340
Password: sa2009ADA
Highlights
This webcast event will feature breaking news from real-life and clinical studies on progress in glycemic control, medication safety, cost-effectiveness, patient well-being and satisfaction. In addition, an update on the sanofi-aventis vision and strategy will further demonstrate the company's commitment to becoming a partner in diabetes healthcare.
Frost & Sullivan Award Reinforces Outstanding Product Line Strategy by SIRS-LabMay 6th, 2009 LONDON - The Frost & Sullivan "2009 European Molecular Diagnostics for Infectious Diseases Product Line Strategy of the Year Award", is presented to SIRS-Lab GmbH. The company's exceptional product line for sepsis diagnosis and monitoring make it a worthy recipient of this award.
Growing Competition Leading to Strategic Consolidations: Hear Frost & Sullivan on the European Diagnostics SpaceApril 28th, 2009 LONDON - The Healthcare Group at Frost & Sullivan is pleased to announce its 2009 Quarterly Analyst Briefing Presentation on the European In-Vitro Diagnostics Market to be held on Thursday, 7th May 2009, at 2 p.m. GMT. (Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)
The global In-Vitro Diagnostics (IVD) market has been witnessing sporadic growth in the past five years with the European sector contributing a third to the total market.
Kenyan Pharmaceutical Industry Can Expect Significant Growth Despite Global Conditions, Finds Frost & SullivanApril 5th, 2009 CAPE TOWN, South Africa - Expanding therapeutic areas are creating significant opportunities for growth within the Kenyan pharmaceutical industry. Although infectious diseases are still responsible for the largest burden of disease in Kenya, non-communicable diseases are becoming a major problem, with the incidence of type II diabetes, cardiovascular disease and cancer increasing rapidly.
Patients' Remote(ly) Monitored: Ask Frost & Sullivan, What Is Driving the European MarketMarch 23rd, 2009 LONDON - The Healthcare Group at Frost & Sullivan is pleased to announce its 2009
Quarterly Analyst Briefing Presentation on the European Remote Patient
Monitoring Market to be held on Tuesday, 31st March 2009, at 2 p.m. GMT. (Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)
The world is facing an ongoing healthcare crisis along with the global
economic slowdown.
Frost & Sullivan Honours Outstanding Achievements in HealthcareMarch 23rd, 2009 LONDON - Global and European Awards recognise Healthcare Excellence
The Healthcare industry's top performers were honoured at Frost &
Sullivan's 'Excellence in Healthcare Awards Banquet' on Thursday 19 March at
ZSL London Zoo, London. (Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )
In a time of economic uncertainty, these awards are a testament to the
Healthcare industry's continued success and growth, with companies awarded
across various disciplines including Product Innovation, Green Excellence,
Product Quality, Research Excellence and Company of the Year.
Related News
An Indian diabetic cure for Hollywood star Halle BerryApril 18th, 2009 NEW DELHI - With an Oscar statuette under her belt, Hollywood is at Halle Berry's feet. However, life has never been a bed of roses for this brilliant actress, as she has had to battle one of the world's most common illnesses - diabetes.
Iron-binding drug may heal diabetes-related stubborn woundsJuly 28th, 2009 WASHINGTON - A drug used to remove iron from the body has the potential to fight the problem of diabetes-related poor wound healing, according to researchers from Stanford University School of Medicine and the Albert Einstein College of Medicine. Poor wound healing is diabetes' cruellest complications, which could lead to amputation of patients' toes, feet, and even legs.
3-D kidney atlas to help researchers, physicians treat renal diseasesMay 16th, 2009 WASHINGTON - In a bid to diagnose and treat renal diseases early and more successfully, researchers from nine European countries have spent four-and-a half years to create a three-dimensional virtual "Kidney Atlas", which incorporates the latest research findings on the development and diseases of the kidney. The Kidney Atlas was part of the European Renal Genome Project (EuReGene), coordinated by the Max Delbruck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, which the European Union (EU) funded with more than 10 million euros.
Amylin Pharmaceuticals asks FDA to approve its once-weekly diabetes drug exenatide LARMay 5th, 2009 Amylin seeks FDA OK on once-weekly diabetes drugNEW YORK — Biotechnology company Amylin Pharmaceuticals Inc. said Tuesday it asked the Food and Drug Administration to approve its highly anticipated once-weekly injectable diabetes treatment exenatide LAR.
India needs a robust and vibrant public health system : AzadSeptember 18th, 2009 NEW DELHI - Union Health and Family Welfare Minister Ghulam Nabi Azad on Friday said that to improve the standard of public health, there is a need for introducing a robust and vibrant public health system in the country. Speaking after presenting the Indian Council of Medical Research (ICMR) awards here Azad said: "To improve the health of the public, we need a robust and vibrant public health system in the country.
Robust growth seen in Indian aviation supplies marketMay 6th, 2009 NEW DELHI - India's civil aviation suppliers market, including components and maintenance, is seen growing annually at 16.1 percent over the next five years to top $3.89 billion, says a new research by a global consultancy. 'Low manufacturing and labour costs are expected to boost outsourcing to India.
Lawyer: NY mon in wrong-way crash 'had a stroke of some sort'; had diabetesAugust 6th, 2009 Lawyer: NY mom in wrong-way crash was diabeticGARDEN CITY, N.Y. — An attorney says the woman who drove drunk and caused a New York highway crash that killed eight people was diabetic and may have suffered a stroke.
Slowdown may dip Indian chip market growth by 50 percentJanuary 27th, 2009 BANGALORE - The global economic slowdown will dip the growth of the semiconductor (chip) market in India by over 50 percent, an industry study said. 'The compound growth of the Indian semicon market for 2009-10 will be 13.4 percent as against the projected 26.7 percent due to lower investment and sluggish manufacturing, resulting in over 50 percent decline,' Indian Semiconductor Association (ISA) chairman Jaswinder Ahuja told reporters Wednesday.
Chronic diseases linked to higher levels of depressionJanuary 15th, 2009 WASHINGTON - People with chronic obstructive pulmonary disease (COPD) are nearly twice as likely to be depressed as diabetics. Dutch researchers compared the health characteristics of 999 patients with COPD, 978 patients with diabetes, and 2,494 healthy control subjects.
Frost too busy for romanceJanuary 11th, 2009 LONDON - British actress Sadie Frost, who has moved on from her marriage with actor Jude Law, says she is too busy with work now to think of romance. According to mirror.co.uk, Frost just returned from a break with Law.
June 24th, 2009 at 11:55 pm
The best way to fight diabetes as a male is to keep testosterone levels in the upper normal range, exercise, and limit refined carb consumption. These 3 things will control blood sugar levels in most men.